{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:09:33Z","timestamp":1792130973372,"version":"4.4.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>To investigate the usage status and evaluate the efficacy of intravenous immunoglobulin (IVIG) for the acute treatment of optic neuritis (ON) in Japan.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Study design<\/jats:title>\n            <jats:p>Multicenter retrospective case series.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The study subjects were patients with steroid-resistant acute ON in whom IVIG had been initiated between January 2020 and August 2022 at 30 facilities in Japan. The clinical characteristics, visual acuity, and adverse events following IVIG were compared among anti-aquaporin 4 antibody positive ON (AQP4-ON), anti-myelin oligodendrocyte glycoprotein antibody positive ON (MOG-ON), and idiopathic ON (ION).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The study included sixty-five patients (76 eyes); the main clinical department administering IVIG was ophthalmology (50 cases, 77.0 %). 43 cases had their first ON attack and 22 cases had recurrent ON. Plasmapheresis (PP) was combined in 21 cases. The efficacy endpoint, changes in logarithm of the minimum angle of resolution (logMAR) after IVIG compared with preIVIG, showed statistically significant improvement in the AQP4-ON group at one week, 4 weeks, and 12 weeks after IVIG (p=0.015, p&lt;0.001, p&lt;0.001, respectively). In the MOG-ON group, excluding cases with combined PP, logMAR post IVIG did not improve significantly compared with preIVIG. Among the ION group, compared with preIVIG, logMAR at 4weeks and 12 weeks post IVIG were statistically significant improved (p=0.019, p=0.023, respectively). Adverse events occurred in 7 patients with IVIG. 4 of the 7 patients continued the IVIG treatment, and 3 patients discontinued it within 5 days.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This study demonstrates that IVIG may be an effective new option for acute treatment of steroid-resistant ON as an add-on to conventional therapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10384-025-01210-6","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T23:14:03Z","timestamp":1747350843000},"page":"775-788","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Intravenous immunoglobulin for the acute treatment of refractory optic neuritis in Japan"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6751-1186","authenticated-orcid":false,"given":"Yohei","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kezuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Shikishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Yamagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Chuman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Ueki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonoko","family":"Tatsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Collaborative Research Group: Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiyo","family":"Mashimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Iguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teppei","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Iwasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotaro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Chihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihito","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Fukuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichiro","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyotaka","family":"Nakamagoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigenari","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norito","family":"Kokubun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Yamanoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Yokouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryutaro","family":"Akiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichiro","family":"Kizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Onda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Tomoyori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurika","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromasa","family":"Sawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Aihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Toriyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuya","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Hikoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miwa","family":"Komori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehiro","family":"Oku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Hirokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsutoshi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayo","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norimitsu","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Sogabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Imanaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"1210_CR1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199202273260901","author":"RW Beck","year":"1992","unstructured":"Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT, Kaufman DI, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992. https:\/\/doi.org\/10.1056\/NEJM199202273260901.","journal-title":"N Engl J Med."},{"key":"1210_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-5155(98)00071-9","author":"M Wakakura","year":"1999","unstructured":"Wakakura M, Mashimo K, Oono S, Matsui Y, Tabuchi A, Kani K, et al. Multicenter clinical trial for evaluating methylprednisolone pulse treatment of idiopathic optic neuritis in Japan. Optic neuritis treatment trial multicenter cooperative research group (ONMRG). Jpn J Ophthalmol. 1999. https:\/\/doi.org\/10.1016\/S0021-5155(98)00071-9.","journal-title":"Jpn J Ophthalmol."},{"key":"1210_CR3","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S1474-4422(22)00200-9","volume":"21","author":"A Petzold","year":"2022","unstructured":"Petzold A, Fraser CL, Abegg M, Alroughani R, Alshowaeir D, Alvarenga R, et al. Diagnosis and classification of optic neuritis. Lancet Neurol. 2022;21:1120\u201334.","journal-title":"Lancet Neurol."},{"key":"1210_CR4","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. (International panel for NMO diagnosis) international consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015. https:\/\/doi.org\/10.1212\/WNL.0000000000001729.","journal-title":"Neurology"},{"key":"1210_CR5","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","volume":"22","author":"B Banwell","year":"2023","unstructured":"Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria. Lancet Neurol. 2023;22:268\u201382.","journal-title":"Lancet Neurol."},{"key":"1210_CR6","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.ophtha.2019.04.042","volume":"126","author":"H Ishikawa","year":"2019","unstructured":"Ishikawa H, Kezuka T, Shikisima K, Yamaguchi A, Hiraoka M, Chuman H, et al. Epidemiologic and clinical characteristics of optic neuritis in Japan. Ophthalmology. 2019;126:1385\u201398.","journal-title":"Ophthalmology."},{"key":"1210_CR7","doi-asserted-by":"publisher","first-page":"932","DOI":"10.3389\/fneur.2020.00932","volume":"11","author":"T Akaishi","year":"2020","unstructured":"Akaishi T, Takeshita T, Himori N, Takahashi T, Misu T, Ogawa R, et al. Rapid administration of high-dose intravenous methylprednisolone improves visual outcomes after optic neuritis in patients with AQP4-IgG-positive NMOSD. Front Neurol. 2020;11:932.","journal-title":"Front Neurol."},{"key":"1210_CR8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/WNO.0000000000000668","volume":"39","author":"EC Contentti","year":"2019","unstructured":"Contentti EC, Virgiliis M, Hryb JP, Gomez A, Morales S, Celso J, et al. Aquaporin-4 serostatus and visual outcomes in clinically isolated acute optic neuritis. J Neuroophthalmol. 2019;39:165\u20139.","journal-title":"J Neuroophthalmol."},{"key":"1210_CR9","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1212\/01.WNL.0000138437.99046.6B","volume":"63","author":"K Ruprecht","year":"2004","unstructured":"Ruprecht K, Klinker E, Dintelmann T, Riekman P, Gold R. Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology. 2004;63:1081\u20133.","journal-title":"Neurology."},{"key":"1210_CR10","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1001\/archophthalmol.2012.1126","volume":"130","author":"H Merle","year":"2012","unstructured":"Merle H, Olindo S, Jeannin S, Valentino R, Mehdaoui H, Cabot F, et al. Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica. Arch Ophthalmol. 2012;130:858\u201362.","journal-title":"Arch Ophthalmol."},{"key":"1210_CR11","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000504","volume":"5","author":"I Kleiter","year":"2018","unstructured":"Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke K-D, Hellwick K, et al. Apheresis therapies for NMOSD attacks. Neurol Neuroimmunol Neuroinflamm. 2018;5: e504.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"1210_CR12","first-page":"424","volume":"29","author":"Y Nakao","year":"2012","unstructured":"Nakao Y, Nakamura Y, Aomatsu K, Sakamoto H. Intravenous immunoglobulin treatment in corticosteroid refractory anti-aquaporin 4 antibody-seropositive optic neuritis. Neuro-Ophthalmol Jpn. 2012;29:424\u201333 ((in Japanese)).","journal-title":"Neuro-Ophthalmol Jpn"},{"key":"1210_CR13","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s10384-020-00790-9","volume":"65","author":"O Mimura","year":"2021","unstructured":"Mimura O, Ishikawa H, Kezuka T, Shikishima K, Suzuki T, Nakamura M, et al. Intravenous immunoglobulin treatment for steroid-resistant optic neuritis: a multicenter, double-blind, randomized, controlled phase III study. Jpn J Ophthalmol. 2021;65:122\u201332.","journal-title":"Jpn J Ophthalmol."},{"key":"1210_CR14","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1212\/WNL.56.11.1514","volume":"56","author":"JH Noseworthy","year":"2001","unstructured":"Noseworthy JH, O\u2019Brien PC, Petterson TM, Weis J, Stevens L, Petersen WK, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology. 2001;56:1514\u201322.","journal-title":"Neurology."},{"key":"1210_CR15","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1212\/01.WNL.0000152873.82631.B3","volume":"64","author":"HG Roed","year":"2005","unstructured":"Roed HG, Langklide A, Sellebjerg F, Lauritzen M, M\u00f8rup A, Fredriksen JL, et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology. 2005;64:804\u201310.","journal-title":"Neurology."},{"key":"1210_CR16","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1212\/WNL.0b013e318248dec1","volume":"78","author":"PJ Waters","year":"2012","unstructured":"Waters PJ, Mckeon A, Leite MI, Rajasekharan S, Lennon VA, Villalobos A, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology. 2012;78:665\u201371.","journal-title":"Neurology."},{"key":"1210_CR17","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0161-6420(99)00133-5","volume":"107","author":"LN Johnson","year":"2000","unstructured":"Johnson LN, Guy ME, Krohel GB, Madsen RW. Levodopa may improve vision loss in recent-onset, nonarteritic anterior ischemic optic neuropathy. Ophthalmology. 2000;107:521\u20136.","journal-title":"Ophthalmology."},{"key":"1210_CR18","first-page":"65","volume":"6","author":"S Holm","year":"1979","unstructured":"Holm S. A simple sequentially rejective multiple test procedure. Scand J Statist. 1979;6:65\u201370.","journal-title":"Scand J Statist"},{"key":"1210_CR19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","volume":"11","author":"JD Lunemann","year":"2015","unstructured":"Lunemann JD, Nimmerjahn F, Dalakas MC. Intravenous immunoglobulin in neurology-mode of action and clinical efficacy. Nat Rev Neurol. 2015;11:80\u20139.","journal-title":"Nat Rev Neurol."},{"key":"1210_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s13311-015-0391-5","volume":"13","author":"JD Lunemann","year":"2016","unstructured":"Lunemann JD, Quast I, Dalakas MC. Efficacy of intravenous immunoglobulin in neurological diseases. Neurotherapeutics. 2016;13:34\u20136.","journal-title":"Neurotherapeutics."},{"key":"1210_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.expneurol.2014.03.004","volume":"255","author":"J Ratelade","year":"2014","unstructured":"Ratelade J, Smith AJ, Verkman AS. Human immunoglobulin G reduces the pathogenicity of aquaporin-4 autoantibodies in neuromyelitis optica. Exp Neurol. 2014;255:145\u201353.","journal-title":"Exp Neurol."},{"key":"1210_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.nrl.2012.03.014","volume":"28","author":"MJ Magraner","year":"2013","unstructured":"Magraner MJ, Coret F, Casenova B. The effect of intravenous immunoglobulin on neuromyelitis optica. Neurologia. 2013;28:65\u201372.","journal-title":"Neurologia."},{"key":"1210_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102325","volume":"44","author":"X Li","year":"2020","unstructured":"Li X, Tian DC, Fan M, Xiu Y, Wang X, Li T, et al. Intravenous immunoglobulin for acute attacks in neuromyelitis optica spectrum disorders (NMOSD). Mult Scler Relat Disord. 2020;44: 102325.","journal-title":"Mult Scler Relat Disord."},{"key":"1210_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2008.02258.x","author":"A Tselis","year":"2008","unstructured":"Tselis A, Perumal J, Caon C, Hreha S, Ching W, Din M, et al. Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin. Eur J Neurol. 2008. https:\/\/doi.org\/10.1111\/j.1468-1331.2008.02258.x.","journal-title":"Eur J Neurol"},{"key":"1210_CR25","first-page":"238","volume":"40","author":"T Mizui","year":"2023","unstructured":"Mizui T, Kezuka T, Kunimi K, Goto H. Intravenous immunoglobulin treatment for steroid-resistant optic neuritis. Neuro-Ophthalmol Jpn. 2023;40:238\u201347 ((in Japanese)).","journal-title":"Neuro-Ophthalmol Jpn"},{"key":"1210_CR26","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1385\/CRIAI:29:3:173","volume":"29","author":"H Orbach","year":"2005","unstructured":"Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol. 2005;29:173\u201384.","journal-title":"Clin Rev Allergy Immunol."},{"key":"1210_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.autrev.2015.09.002","volume":"15","author":"P Cherin","year":"2016","unstructured":"Cherin P, Marie I, Michallet M, Pelus E, Dantal J, Crave J-C, et al. Management of adverse events in the treatment of patients with immunoglobulin therapy: a review of evidence. Autoimmun Rev. 2016;15:71\u201381.","journal-title":"Autoimmun Rev."},{"key":"1210_CR28","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","volume":"9","author":"Y Guo","year":"2018","unstructured":"Guo Y, Tian X, Wang X, Xiao Z. Adverse effects of immunoglobulin therapy. Front Immunol. 2018;9:1299.","journal-title":"Front Immunol."}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01210-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-025-01210-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01210-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T15:04:28Z","timestamp":1757171068000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-025-01210-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1210"],"URL":"https:\/\/doi.org\/10.1007\/s10384-025-01210-6","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"23 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y. Takahashi, None; T. Kezuka, Nonfinancial support (UCB, Chugai, Cosmic Corp, Mitsubishi Tanabe, Santen, Senju, Teijin, Nitto Medic, ALEXION, Takeda, Novartis, AbbVie); Consulting fees (UCB, Chugai, ALEXION), Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Chugai, Teijin, AbbVie, Mitsubishi Tanabe, Cosmic Corp, Santen, Senju, Teijin, Takeda, Novartis, Nitto Medic, ALEXION); K. Shikishima, None; A. Yamagami, None; H. Chuman, None; M. Nakamura, None; S. Ueki, None; A. Kimura, None; M. Hashimoto, None; S. Tatsui, None; N. Shoji, None; H. Ishikawa, Nonfinancial support (Santen, Chugai, ALEXION), Consulting fees (Chugai, Santen, ALEXION).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}